Seek Returns

AZN vs. MRK: AstraZeneca vs. Merck Stock Comparison

How do AstraZeneca (AZN) and Merck (MRK) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AstraZeneca (AZN) and Merck (MRK) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Merck (MRK) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for AstraZeneca (AZN) and Merck (MRK)
Profile ItemAZNMRK
NameAstraZeneca PLC American Depositary SharesMerck & Co., Inc.
Country/RegionUnited KingdomUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization242.64 billion USD335.14 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMay 12, 1993January 2, 1962
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

AZN
MRK
GSPC
Loading price history…
AstraZeneca (AZN) vs. Merck (MRK), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AstraZeneca (AZN) and Merck (MRK). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AstraZeneca (AZN) and Merck (MRK). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
Total Return (1Y)0.73%69.62%
Total Return (3Y, Annualized)5.20%11.01%
Total Return (5Y, Annualized)8.07%15.66%

Risk Profile

Drawdown History

AZN
MRK
GSPC
Loading price history…
AstraZeneca (AZN) vs. Merck (MRK), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AstraZeneca (AZN) and Merck (MRK). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
Volatility (1Y, Annualized)28.07%27.48%
Beta (5Y)0.240.20
Max Drawdown (5Y)-27.87%-43.44%
Avg. Volume (3M)2.81M10.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AZN and MRK are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
Sharpe Ratio (1Y)-0.122.39
Sortino Ratio (1Y)-0.174.18

Profitability

ROE (TTM)

Both AstraZeneca (AZN) at 21.97% and Merck (MRK) at 6.96% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.97%

Max
102.29%
AZN
21.97%
Q3
3.11%
Median
-33.05%
Q1
-64.06%
Min
-157.61%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96%

Max
102.29%
MRK
6.96%
Q3
3.11%
Median
-33.05%
Q1
-64.06%
Min
-157.61%
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

AstraZeneca (AZN) at 17.02% keeps the most of each sales dollar — above its industry’s net margin range — and Merck (MRK) at 4.77% also retains a top-quartile share.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.02%

AZN
17.02%
Max
12.02%
Q3
2.01%
Median
0.00%
Q1
-5.21%
Min
-13.51%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.77%

Max
12.02%
MRK
4.77%
Q3
2.01%
Median
0.00%
Q1
-5.21%
Min
-13.51%
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Merck (MRK) reports a negative operating margin of -0.24%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile AstraZeneca (AZN) reports 23.46%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.46%

Max
76.04%
AZN
23.46%
Q3
9.50%
Median
0.00%
Q1
-121.15%
Min
-308.66%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.24%

Max
76.04%
Q3
9.50%
Median
0.00%
MRK
-0.24%
Q1
-121.15%
Min
-308.66%
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
ROE (TTM)21.97%6.96%
ROA (TTM)8.02%11.87%
Net Margin (TTM)17.02%4.77%
Operating Margin (TTM)23.46%-0.24%
Gross Margin (TTM)81.69%75.90%

Growth

Revenue Growth

Both AstraZeneca (AZN) at 8.63% and Merck (MRK) at 1.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AstraZeneca (AZN) at 45.33% and Merck (MRK) at 8.01% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
Revenue Growth (YoY)8.63%1.31%
Revenue Growth (3Y CAGR)9.82%3.12%
EPS Growth (YoY)45.33%8.01%
EPS Growth (3Y CAGR)45.80%8.43%

Financial Strength

Current Ratio (MRQ)

Both AstraZeneca (AZN) at 0.89 and Merck (MRK) at 1.32 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.89

Max
26.78
Q3
12.59
Median
5.76
Q1
2.84
AZN
0.89
Min
0.10

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
26.78
Q3
12.59
Median
5.76
Q1
2.84
MRK
1.32
Min
0.10
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both AstraZeneca (AZN) at 0.64 and Merck (MRK) at 1.28 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.64

Max
1.38
AZN
0.64
Q3
0.63
Median
0.13
Q1
0.02
Min
0.00

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.28

Max
1.38
MRK
1.28
Q3
0.63
Median
0.13
Q1
0.02
Min
0.00
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
Current Ratio (MRQ)0.891.32
Debt / Equity (MRQ)0.641.28
Net Debt / EBITDA1.381.62

Dividends

Dividend Yield (TTM)

Both AstraZeneca (AZN) at 2.05% and Merck (MRK) at 2.45% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05%

AZN
2.05%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45%

MRK
2.45%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Merck (MRK) reports payout ratio above 100% at 268.80%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile AstraZeneca (AZN) reports 47.41%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

47.41%

AZN
47.41%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

268.80%

MRK
268.80%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
Dividend Yield (TTM)2.05%2.45%
Dividend Payout Ratio (TTM)47.41%268.80%

Valuation

P/E Ratio (TTM)

AstraZeneca (AZN) at 23.42 is near its industry’s usual P/E ratio, while Merck (MRK) at 108.67 sits above its peer range — an unusually expensive price for MRK’s trailing earnings.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.42

Max
84.64
Q3
44.87
Median
27.73
AZN
23.42
Q1
16.02
Min
0.13

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

108.67

MRK
108.67
Max
84.64
Q3
44.87
Median
27.73
Q1
16.02
Min
0.13
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AstraZeneca (AZN) at 3.95 and Merck (MRK) at 5.03 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.95

Max
75.52
Q3
33.02
Median
7.47
AZN
3.95
Q1
3.59
Min
0.01

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.03

Max
75.52
Q3
33.02
Median
7.47
MRK
5.03
Q1
3.59
Min
0.01
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AstraZeneca (AZN) at 4.82 is valued about in line with its industry on P/B ratio, while Merck (MRK) at 8.00 carries an above-peer premium to book — MRK is pricier on assets.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.82

Max
15.44
Q3
7.74
AZN
4.82
Median
4.00
Q1
1.86
Min
-6.35

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.00

Max
15.44
MRK
8.00
Q3
7.74
Median
4.00
Q1
1.86
Min
-6.35
Loading chart…
AstraZeneca (AZN) vs. Merck (MRK): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AstraZeneca (AZN) and Merck (MRK)
MetricAZNMRK
P/E Ratio (TTM)23.42108.67
P/S Ratio (TTM)3.955.03
P/B Ratio (MRQ)4.828.00
Free Cash Flow Yield (TTM)2.02%4.53%